Latest news with #AUTL
Yahoo
20-05-2025
- Automotive
- Yahoo
Autolus Therapeutics plc (AUTL): Analysts See 697% Upside Potential
We recently published an article titled . Autolus Therapeutics plc (NASDAQ:AUTL) was one of the stocks that was covered in that article. Wall Street analysts believe AUTL has a 697% upside potential over the next 12 months. A laboratory technician carefully studying a microscope with a biopharmaceutical product inside. Autolus Therapeutics plc (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company specializing in the development of T-cell therapies for the treatment of cancer and autoimmune diseases. Established in 2014, Autolus is advancing innovative approaches in the field of chimeric antigen receptor (CAR) T-cell therapy, aiming to transform patient outcomes with cutting-edge science and technology. Autolus has strategically positioned itself to meet global demand through its dedicated commercial manufacturing facility, known as "The Nucleus," located in the UK. This facility not only supports clinical and commercial production requirements but also ensures scalability and flexibility, enabling the company to cater to expanding markets. Autolus retains worldwide commercial rights to its products and maintains a focused marketing strategy targeting key regions such as the United States, the United Kingdom, and Europe. This strategic approach highlights the company's commitment to delivering transformative therapies across diverse geographic markets while ensuring the highest standards of quality in production. Further analysis of the company's business model and financial performance reflect its significant progress in advancing CAR T-cell therapy. In the first quarter of 2025, Autolus posted revenue of $9 million, demonstrating steady growth. For the full year of 2024, the company reported $45.8 million in revenue, driven by its pioneering efforts in cancer treatment development. With $210 million in cash reserves, Autolus is well-positioned to support the commercialization plans for its therapies and sustain future research and development endeavors. This financial stability has contributed to a positive outlook among analysts, who project the company's share price to reach $9.97 within the next twelve months, offering an upside potential of 697.60%. Through its relentless pursuit of innovation and financial health, Autolus Therapeutics plc remains at the forefront of oncology treatment, pushing boundaries and redefining possibilities in CAR T-cell therapy. Overall, Autolus Therapeutics plc (NASDAQ:AUTL) ranks 3rd on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of AUTL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AUTL and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
02-04-2025
- Automotive
- Yahoo
Autolus Therapeutics price target lowered to $10 from $11 at Truist
Truist lowered the firm's price target on Autolus Therapeutics (AUTL) to $10 from $11 and keeps a Buy rating on the shares. The firm is updating its model and estimates for Autolus, slightly lowering our price target as it removes AUTO4 from its valuation, the analyst tells investors in a research note. Truist adds it is assigning no value to autoimmune indications, but this could change following Autolus' April R&D day. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on AUTL: Disclaimer & DisclosureReport an Issue Autolus Therapeutics: Positive Momentum Amid Financial Challenges Autolus Therapeutics price target lowered to $6 from $8 at Wells Fargo Positive Outlook and Buy Rating for Autolus Therapeutics Driven by Strategic Developments and Promising Prospects Autolus Therapeutics Reports Strong 2024 Results Optimistic Buy Rating for Autolus Therapeutics Driven by Strategic Advancements and Successful Launch of Aucatzyl Sign in to access your portfolio
